Provided by Tiger Fintech (Singapore) Pte. Ltd.

Celldex Therapeutics

19.57
-0.0100-0.05%
Post-market: 19.570.00000.00%16:05 EDT
Volume:377.56K
Turnover:7.34M
Market Cap:1.30B
PE:-7.98
High:19.65
Open:19.32
Low:18.91
Close:19.58
Loading ...

Company Profile

Company Name:
Celldex Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
186
Office Location:
Perryville III Building,Suite 220,53 Frontage Road,Hampton,New Jersey,United States
Zip Code:
08827
Fax:
908 454 1911
Introduction:
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Directors

Name
Position
Anthony S. Marucci
President and Chief Executive Officer, Director
Larry Ellberger
Chairman of the Board of Directors
Gerald McMahon
Director
Harry H. Penner, Jr.
Director
Herbert J. Conrad
Director
James J. Marino
Director
Karen L. Shoos
Director
Keith L. Brownlie
Director

Shareholders

Name
Position
Anthony S. Marucci
President and Chief Executive Officer, Director
Avery W. Catlin
Senior Vice President, Chief Financial Officer and Secretary
Elizabeth Crowley
Senior Vice President and Chief Product Development Officer
Richard Wright
Senior Vice President and Chief Commercial Officer
Ronald Pepin
Senior Vice President and Chief Business Officer
Theresa LaVallee
Senior Vice President, Regulatory and Precision Medicine
Thomas Davis
Executive Vice President and Chief Medical Officer
Tibor Keler
Executive Vice President and Chief Scientific Officer